FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Radov A. Jeffrey
2. Issuer Name and Ticker or Trading Symbol

BioRestorative Therapies, Inc. [ BRTX ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director                      _____ 10% Owner
_____ Officer (give title below)      _____ Other (specify below)
(Last)          (First)          (Middle)

8 WALWORTH AVENUE
3. Date of Earliest Transaction (MM/DD/YYYY)

10/29/2018
(Street)

SCARSDALE, NY 10583
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock                  12500   D    

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option   $4.7                      (1) 2/9/2022   Common Stock   30000     30000   D    
Stock Option   $4.7                      (2) 12/7/2022   Common Stock   5000     5000   D    
Stock Option   $4.7                      (3) 10/4/2023   Common Stock   12500     12500   D    
Stock Option   $4.7                      (4) 2/18/2024   Common Stock   25000     25000   D    
Stock Option   $4.7                      (5) 10/23/2024   Common Stock   50000     50000   D    
Stock Option   $4.7                      (6) 9/4/2025   Common Stock   115500     115500   D    
Stock Option   $3.73                      (7) 6/10/2026   Common Stock   128000     128000   D    
Stock Option   $3.35                      (8) 6/23/2027   Common Stock   125000     125000   D    
Stock Option   $1.23   10/29/2018     A      75000         (9) 10/29/2028   Common Stock   75000   $0   75000   D    

Explanation of Responses:
(1)  The option is exercisable to the extent of 15,000 shares on each of February 10, 2012 and February 10, 2013.
(2)  The option is exercisable to the extent of 2,500 shares on each of December 7, 2012 and December 7, 2013.
(3)  The option is exercisable to the extent of 6,250 shares on each of October 4, 2013 and October 4, 2014.
(4)  The option is exercisable to the extent of 8,334 shares on February 18, 2014, and 8,333 shares on each of February 18, 2015 and February 18, 2016.
(5)  The option is exercisable to the extent of 16,667 shares on each of October 23, 2015 and Octobe 23, 2016 and 16,666 shares on October 23, 2017.
(6)  The option is exercisable to the extent of 57,750 shares on December 22, 2015, and 19,250 shares on each of September 4, 2016, September 4, 2017 and September 4, 2018.
(7)  The option is exercisable to the extent of 42,667 shares on each of June 10, 2016 and June 10, 2017, and 42,666 shares on June 10, 2018.
(8)  The option is exercisable to the extent of 41,667 shares on each of June 23, 2017 and June 23, 2018, and 41,666 shares on June 23, 2019.
(9)  The option is exercisable to the extent of 25,000 shares on each of October 29, 2018, October 29, 2019 and October 29, 2020.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Radov A. Jeffrey
8 WALWORTH AVENUE
SCARSDALE, NY 10583
X



Signatures
/s/ A. Jeffrey Radov 10/30/2018
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.